Back Hepatitis C

Hepatitis C

CROI 2015: Good Sofosbuvir/Ledipasvir Adherence in SYNERGY and ERADICATE Trials

Overall adherence rates ranged from 96% to nearly 100% in 2 clinical trials of sofosbuvir/ledipasvir (Harvoni) treatment in an urban population of hepatitis C and HIV/HCV coinfected patients traditionally considered difficult to treat, researchers reported at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. Adherence dropped off over time, however, underlining the importance of short-duration therapy.

alt

CROI 2015: HCV Sexual Transmission Linked to Anal Sex, Drug Use, Lower CD4 Count

In addition to the usual risk factors for hepatitis C virus (HCV) sexual transmission seen in most previous studies -- such as anal sex and having other sexually transmitted infections -- researchers in the Netherlands also saw an association with nasal and injection drug use and lower CD4 T-cell count, they reported in a poster presentation at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

CROI 2015: Sustained Virological Response Represents a Long-term Cure for Hepatitis C

Almost all patients with hepatitis C virus alone or HIV/HCV coinfection who achieved sustained virological response (SVR) to treatment with sofosbuvir (Sovaldi) plus ribavirin or sofosbuvir/ledipasvir (Harvoni) still had undetectable HCV RNA up to 2.4 years later, confirming that SVR represents a cure, according to a poster presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

FDA Warns of Heart Risk When Combining Amiodarone with Sovaldi or Harvoni

The new oral hepatitis C drug sofosbuvir, either in the sofosbuvir/ ledipasvir coformulation (Harvoni) or with other direct-acting antivirals, should not be taken with the anti-arrhythmic medication amiodarone, the U.S. Food and Drug Association (FDA) and Gilead Sciences warned after several patients developed decreased heart rate (bradycardia) and 1 had a fatal heart attack when they combined these drugs.

alt

CROI 2015: Hepatitis C -- Mission Accomplished? [VIDEO]

New interferon-free treatment for hepatitis C virus (HCV) has brought about a revolution in treatment, but challenges still remain -- among them too few people with HCV being diagnosed and the high cost of the new drugs -- before the mission can be declared a success. A panel of hepatitis C experts discuss research presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections(CROI) in Seattle with HIVandHepatitis.com editor Liz Highleyman in this IFARA video.

alt

FDA Will Consider Approval of Daclatasvir for Genotype 3 Hepatitis C Treatment

The U.S. Food and Drug Administration (FDA) has accepted Bristol-Myers Squibb's application for approval of stand-alone daclatasvir (Daklinza) for the treatment of genotype 3 hepatitis C virus (HCV), to be used in combination with sofosbuvir (Sovaldi), the company announced last week.

alt

CROI 2015: Liver Disease Progression Is Common Among Baby Boomers with Hepatitis C

The burden of hepatitis C virus (HCV) infection is high in the U.S., with nearly half of HCV-infected individuals born between 1945 and 1965 having severe fibrosis or cirrhosis and therefore being at high priority for treatment, according to a report presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle.

alt

CROI 2015: Re-infection Due to Ongoing Risk Is Probably the Cause of HCV Recurrence After SVR

Rates of hepatitis C virus (HCV) recurrence after successful therapy differ markedly between risk groups, according to the results of a meta-analysis presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

New Hepatitis C Treatments Highly Effective for HIV/HCV Coinfected People

A pair of interferon-free combinations -- AbbVie's 3-drug Viekira Pak regimen and Gilead Science's sofosbuvir/ledipasvir (Harvoni) -- demonstrated good safety and cured more than 90% of genotype 1 HIV/HCV coinfected people, according to studies published in the February 23 advance edition of the Journal of the American Medical Association.

alt